A long-acting isomer of Ac-SDKP attenuates pulmonary fibrosis through SRPK1-mediated PI3K/AKT and Smad2 pathway inhibition.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- A long-acting isomer of Ac-SDKP attenuates pulmonary fibrosis through SRPK1-mediated PI3K/AKT and Smad2 pathway inhibition.
- Published In:
- IUBMB life, 72(12), 2611-2626 (2020)
- Authors:
- Qiu, Yueyuan, Wang, Zhaowei, Zhang, Xutao, Huang, Ping, Zhang, Wangqian, Zhang, Kuo, Wang, Shuning, He, Lei, Guo, Yanhai, Xiang, An, Zhang, Cun, Hao, Qiang, Li, Meng, Li, Weina, Zhang, Yingqi
- Database ID:
- RPEP-05083
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-05083APA
Qiu, Yueyuan; Wang, Zhaowei; Zhang, Xutao; Huang, Ping; Zhang, Wangqian; Zhang, Kuo; Wang, Shuning; He, Lei; Guo, Yanhai; Xiang, An; Zhang, Cun; Hao, Qiang; Li, Meng; Li, Weina; Zhang, Yingqi. (2020). A long-acting isomer of Ac-SDKP attenuates pulmonary fibrosis through SRPK1-mediated PI3K/AKT and Smad2 pathway inhibition.. IUBMB life, 72(12), 2611-2626. https://doi.org/10.1002/iub.2389
MLA
Qiu, Yueyuan, et al. "A long-acting isomer of Ac-SDKP attenuates pulmonary fibrosis through SRPK1-mediated PI3K/AKT and Smad2 pathway inhibition.." IUBMB life, 2020. https://doi.org/10.1002/iub.2389
RethinkPeptides
RethinkPeptides Research Database. "A long-acting isomer of Ac-SDKP attenuates pulmonary fibrosi..." RPEP-05083. Retrieved from https://rethinkpeptides.com/research/qiu-2020-a-longacting-isomer-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.